Correspondence 0001013762-25-003778 from Jyong Biotech Ltd. (MENS)
Jyong Biotech Ltd.
Date: March 28, 2025 · CIK: 0001954488 · Accession: 0001013762-25-003778
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-277725
Letter
Joseph Stone Capital, LLC
March 28, 2025
VIA EDGAR
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Attention: Ms. Doris Stacey Gama/ Ms. Suzanne Hayes
Re: Jyong Biotech Ltd.
Registration Statement on Form F-1, as amended
File No. 333-277725
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended (the "Act"), as the underwriter of the proposed offering of Jyong Biotech Ltd. (the "Company"), we hereby join the Company's request for acceleration of the above-referenced Registration Statement, requesting effectiveness for 4:00 p.m., Eastern Time, on Monday, March 31, 2025, or as soon thereafter as is practicable.
Pursuant to Rule 460 under the Act, as the representative of the several underwriters, we wish to advise you that we have distributed to each underwriter and dealer who is reasonably anticipated to participate in the distribution of the security to be offered a sufficient number of copies of the preliminary prospectus permitted by Rule 430 under the Act as it appears to be reasonable to secure their adequate distribution.
The undersigned advises that it has complied and will continue to comply with the requirements of Rule 15c2-8 under the Securities and Exchange Act of 1934, as amended.
Very Truly Yours,
Joseph Stone Capital, LLC
Show Raw Text
CORRESP 1 filename1.htm Joseph Stone Capital, LLC March 28, 2025 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Ms. Doris Stacey Gama/ Ms. Suzanne Hayes Re: Jyong Biotech Ltd. Registration Statement on Form F-1, as amended File No. 333-277725 Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as amended (the "Act"), as the underwriter of the proposed offering of Jyong Biotech Ltd. (the "Company"), we hereby join the Company's request for acceleration of the above-referenced Registration Statement, requesting effectiveness for 4:00 p.m., Eastern Time, on Monday, March 31, 2025, or as soon thereafter as is practicable. Pursuant to Rule 460 under the Act, as the representative of the several underwriters, we wish to advise you that we have distributed to each underwriter and dealer who is reasonably anticipated to participate in the distribution of the security to be offered a sufficient number of copies of the preliminary prospectus permitted by Rule 430 under the Act as it appears to be reasonable to secure their adequate distribution. The undersigned advises that it has complied and will continue to comply with the requirements of Rule 15c2-8 under the Securities and Exchange Act of 1934, as amended. Very Truly Yours, Joseph Stone Capital, LLC By: /s/ Damian Maggio Name: Damian Maggio Title: Chief Executive Officer cc: Fang Liu, Esq. of VCL Law LLP